Effects of bis(7)-tacrine, a novel anti-Alzheimerʼs agent, on rat brain AChE
- 17 March 1999
- journal article
- neuropharmacology
- Published by Wolters Kluwer Health in NeuroReport
- Vol. 10 (4) , 789-793
- https://doi.org/10.1097/00001756-199903170-00023
Abstract
The anticholinesterase effects of bis(7)-tacrine were compared with tacrine in vitro and in vivo. Based on IC50 ratios, the dimeric analog bis(7)-tacrine was, in a reversible manner, up to 150-fold more potent and 250-fold more selective than tacrine for acetylcholinesterase (AChE) over butyrylcholinesterase (BChE). Following a single oral administration, both bis(7)-tacrine and tacrine produced dose-dependent inhibitions of AChE in rat brain, but bis(7)-tacrine exhibited higher efficacy and AChE/BChE sclectivity than tacrine. The anti-AChE efficacy of bis(7)-tacrine was quite similar following an oral or i.p. administration, but tacrine showed much lower efficacy when administered orally than when given i.p. These findings suggest bis(7)-tacrine, a highly potent and selective inhibitor of AChE, can probably be used as an improved drug in the palliative treatment of AD.Keywords
This publication has 3 references indexed in Scilit:
- Prediction of the binding sites of huperzine A in acetylcholinesterase by docking studiesJournal of Computer-Aided Molecular Design, 1994
- Tacrine: A pharmacological reviewProgress in Neurobiology, 1991
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976